Drug Type Small molecule drug |
Synonyms PF 5089771, PF-5089771 |
Target |
Mechanism Nav1.7 blockers(Sodium channel protein type IX alpha subunit blockers), Nav1.8 blockers(Sodium channel protein type X alpha subunit blockers) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC18H12Cl2FN5O3S2 |
InChIKeyZYSCOUXLBXGGIM-UHFFFAOYSA-N |
CAS Registry1235403-62-9 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | PF-05089771 | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Diabetic peripheral neuropathy | Phase 2 | US | 10 Nov 2014 | |
Erythromelalgia | Phase 2 | US | 22 Oct 2012 | |
Toothache | Phase 2 | US | 12 Dec 2011 | |
Neuralgia | Phase 2 | - | - | |
Pain | Phase 1 | NL | 01 Jan 2015 | |
Osteoarthritis, Knee | Phase 1 | BE | 01 Jan 2012 |
Phase 2 | 235 | placebo+PF-05089771 (PF-05089771 150 mg) | uivoctbcit(yavjvznkfe) = aaykvnhdua zyrwkjhzpi (oyrtnuoxkh, njwsxzehkx - hnnviddohu) View more | - | 01 Jun 2018 | ||
placebo+PF-05089771 (PF-05089771 450 mg) | uivoctbcit(yavjvznkfe) = xzafnvjtjq zyrwkjhzpi (oyrtnuoxkh, hduqvccxwh - rkserkjkev) View more | ||||||
Phase 2 | 141 | (Pregabalin) | xlxpxstrwj(qcfnlznffh) = gfmddzouoh ximankpdnw (wefhhgjqkp, izapiccojj - gbigewpqsk) View more | - | 05 May 2017 | ||
Matched placebo for PF-05089771 150 mg (Placebo) | xlxpxstrwj(qcfnlznffh) = btdbbvobpl ximankpdnw (wefhhgjqkp, oqauchabhg - crmhrtznvz) View more |